Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies

Abstract Intrahepatic cholangiocarcinoma (ICC) remains a deadly malignancy lacking systemic therapies for advanced disease. Recent advancements include selective FGFR1–3 inhibitors for the 15% of ICC patients harboring fusions, although survival is limited by poor response and resistance. Herein we...

Full description

Bibliographic Details
Main Authors: Michael E. Lidsky, Zechen Wang, Min Lu, Annie Liu, S. David Hsu, Shannon J. McCall, Zhecheng Sheng, Joshua A. Granek, Kouros Owzar, Karen S. Anderson, Kris C. Wood
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00320-5

Internet

https://doi.org/10.1038/s41698-022-00320-5

Similar Items